Eiger BioPharmaceuticals, Inc
350 Cambridge Ave, Suite 350
Palo Alto
CA
94306
United States
168 articles about Eiger BioPharmaceuticals, Inc
-
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
11/9/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.
-
Following cases of hepatobiliary toxicity leading to liver decompensation, Eiger has decided to drop its Phase III LIMT-2 trial of peginterferon lambda in chronic hepatitis delta.
-
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta
9/12/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD).
-
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY.
-
Many products are facing the loss of their patents or exclusivity clauses. Here’s what to expect in the coming months.
-
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8/14/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today reported financial results for the second quarter 2023 and provided a business update.
-
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO
6/29/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycemia indications.
-
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow
6/28/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET.
-
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2023 and provided a business update.
-
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - May 03, 2023
5/3/2023
Eiger BioPharmaceuticals, Inc. reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock.
-
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments
4/13/2023
Eiger BioPharmaceuticals, Inc. today announced the appointments of William G. Kachioff as Chief Financial Officer, and James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary.
-
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/16/2023
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update.
-
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
2/8/2023
Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM).
-
Eiger BioPharmaceuticals Announces Leadership Change
12/15/2022
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, and its Board of Directors announced that David A. Cory has resigned as President, Chief Executive Officer and member of the Board of Directors, effective immediately.
-
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
12/8/2022
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced topline primary Week 48 data from its landmark Phase 3 D-LIVR study (N=407) evaluating lonafarnib, a first-in-class prenylation inhibitor, in two regimens in patients with chronic HDV: lonafarnib boosted with ritonavir alone (all-oral) and in combination with peginterferon alfa (combination).
-
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022
12/7/2022
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.
-
Eiger BioPharmaceuticals to Participate in Upcoming November 2022 Investor Conferences
11/8/2022
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, announced that members of its management team will participate in the following upcoming investor conferences.
-
Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
11/3/2022
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for third quarter 2022 and provided a business update.
-
Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3
10/24/2022
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.
-
Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference
10/11/2022
Eiger BioPharmaceuticals, Inc. today announced that David Cory , President and CEO, will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference on Tuesday, October 18, 2022 at 3:00 PM ET.